Human Recombinant Epidermal Growth Factor in skin lesions: 77 cases in EPItelizando Project.

Human Recombinant Epidermal Growth Factor in skin lesions: 77 cases in EPItelizando Project.

J Dermatolog Treat. 2018 Apr 23;:1-23

Authors: Esquirol-Caussa J, Herrero-Vila E

Abstract
OBJECTIVE: To analyze compounded recombinant human Epidermal Growth Factor (rhEGF) effectiveness on skin lesions through a case series.
DESIGN: Multicentric series of skin lesions treated with topical recombinant human Epidermal Growth Factor. SITE: Patients from 56 different health professionals, three different countries, two recruitment years.
PARTICIPANTS: 77 patients with skin lesions, mean age 63.15 years (min = 18, max = 95); 53.2% were men and 46.8% women; 47 of the lesions were ulcers (venous, arterial, diabetic foot), other were surgical and traumatic wounds, burns, scars. Most common pathologies were Type 2 Diabetes Mellitus and Chronic Venous Insufficiency. Mean previous evolution time before inclusion: 29.59 months.
INTERVENTIONS: Cures using compounded topical human recombinant Epidermal Growth Factor; most commonly used rhEGF concentration: 30μg/g; most used excipient: gel; average time between cures: 36 hours (24-48); mean follow-up: 6.6 weeks (maximum = 20).
MAIN MEASUREMENTS: Lesions appearance, margins and bed, lesional size evolution, treatment subjective effectiveness, tolerability and comfort through professional oppinion.
RESULTS AND CONCLUSIONS: Qualitative assessment: effectiveness 8.65, tolerability 9.53, comfort 8.86 (maximum: 10). Perilesional skin showed improvement in 93.5% of the cases, lesions margins and wound bed appearance improved in 92.2% of the cases, respectively. Wound area decreased a mean average of 66.7%. 43.3% of included venous ulcers had a greater than 40% cure rate in 4 weeks.
LIMITATIONS: heterogeneity of the included pathologies, limited time follow-up in some cases.
CONCLUSIONS: topical recombinant human Epidermal Growth Factor in individualized formulation (compounding) seems to exhibit effectiveness, comfort and tolerability. Further larger size studies with experimental design will allow to establish more precise concentrations, indications and clinical guidelines.

PMID: 29683361 [PubMed - as supplied by publisher]

https://ift.tt/2JlbvwZ